Literature DB >> 19298720

Fluorescent in situ hybridization studies in multiple myeloma.

Ozge Ozalp Yuregir1, Feride Iffet Sahin, Zerrin Yilmaz, Ebru Kizilkilic, Sema Karakus, Hakan Ozdogu.   

Abstract

Conventional cytogenetic analysis and fluorescence in situ hybridization (FISH) results of bone marrow samples of 36 multiple myeloma (MM) patients at the time of diagnosis have been evaluated. Three probes for chromosome 13q (RB1, D13S319, D13S25), one for 14q32 (IgH) and one for 17p13 (p53) have been used for hybridization with fixed cells. Twenty patients (55.5%) had normal karyotypes, whereas eight (22.2%) had numerical or structural chromosomal abnormalities. We did not find metaphases for chromosome analysis in eight (22.2%) patients. Fluorescence in situ hybridization analyses revealed at least one or more abnormal results in 25 (69.5%) cases, whereas 11(30.5%) cases had no abnormal findings. 14q32 rearrangement was the most common finding in FISH analyses and has been detected in 21 cases (58.3%). 13q deletion and 17p deletion have been detected in 11 (30.5%) and 5 (13.9%) cases, respectively. Fluorescence in situ hybridization studies including 14q32 and 17p13 chromosome regions may yield quite significant results during clinical follow-up of MM.

Entities:  

Mesh:

Year:  2009        PMID: 19298720     DOI: 10.1179/102453309X385250

Source DB:  PubMed          Journal:  Hematology        ISSN: 1024-5332            Impact factor:   2.269


  7 in total

1.  Fluorescence in situ hybridization analysis of chromosome aberrations in 60 Chinese patients with multiple myeloma.

Authors:  Xiao Gao; Chunming Li; Run Zhang; Ruifang Yang; Xiaoyan Qu; Hairong Qiu; Jiaren Xu; Hua Lu; Jianyong Li; Lijuan Chen
Journal:  Med Oncol       Date:  2011-05-25       Impact factor: 3.064

2.  Clinical utility of FISH analysis in addition to G-banded karyotype in hematologic malignancies and proposal of a practical approach.

Authors:  Won Kyung Kwon; Jin Young Lee; Yeung Chul Mun; Chu Myong Seong; Wha Soon Chung; Jungwon Huh
Journal:  Korean J Hematol       Date:  2010-09-30

3.  IRF4 promotes cell proliferation by JNK pathway in multiple myeloma.

Authors:  Sensen Zhang; Jiaren Xu; Shuang Wu; Rong Wang; Xiaoyan Qu; Wenjun Yu; Jiangyong Li; Lijuan Chen
Journal:  Med Oncol       Date:  2013-05-12       Impact factor: 3.064

4.  p53 haploinsufficiency and functional abnormalities in multiple myeloma.

Authors:  P J Teoh; T H Chung; S Sebastian; S N Choo; J Yan; S B Ng; R Fonseca; W J Chng
Journal:  Leukemia       Date:  2014-03-14       Impact factor: 11.528

5.  Cytogenetic Abnormalities in Multiple Myeloma Patients at a Tertiary Healthcare Center in India

Authors:  Perumal Govindasamy; Prabu Pandurangan; Anil Tarigopula; Rama Mani; Chandra R Samuel
Journal:  Asian Pac J Cancer Prev       Date:  2019-01-25

6.  Evaluation of chromosomal abnormalities by cIg-FISH and association with proliferative and apoptotic indexes in multiple myeloma.

Authors:  C C G Linardi; G Martinez; E D R P Velloso; A M Leal; C A Kumeda; V Buccheri; R S Azevedo; L M Peliçario; P Dorlhiac-Llacer
Journal:  Braz J Med Biol Res       Date:  2012-08-23       Impact factor: 2.590

7.  Globular C1q Receptor (gC1qR/p32/HABP1) Suppresses the Tumor-Inhibiting Role of C1q and Promotes Tumor Proliferation in 1q21-Amplified Multiple Myeloma.

Authors:  Jiadai Xu; Yifeng Sun; Jifeng Jiang; Zhao Xu; Jing Li; Tianhong Xu; Peng Liu
Journal:  Front Immunol       Date:  2020-07-14       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.